Wells Fargo Lowers Amphastar Pharmaceuticals' Price Target to $19
Wells Fargo downgraded Amphastar Pharmaceuticals (NASDAQ:AMPH) from Overweight to Equal Weight, reducing its price target from $30 to $19. The downgrade stems from uncertainty regarding the company's revenue trajectory for 2026 and 2027, as well as concerns over AMP-004’s interchangeability status.
